In treatment of advanced-stage NSCLC, ICI combination therapies such as nivolumab plus the anti-CTLA-4 antibody ipilimumab showed superior efficacy over chemotherapy irrespective of the PD-L1 status (e.g., CheckMate 227) [35]. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.